多西他赛联合mFOLFOX方案治疗进展期胃癌的疗效评价

目的研究多西他赛联合mFOLFOX方案化疗治疗进展期胃癌的疗效及其毒副作用。方法31例患者应用该方案起止时间为2005年6月至2007年3月。化疗方案：多西他赛60mg/m2,d1,滴注;OXA130mg/m2,d2,滴注;5-Fu2.8g/m2,civ,46h;CF300mg,d2,5-Fu前2h滴注,每3周为1周期,至少应用2周期。观察应用该方案肿瘤缓解情况及化疗的毒副反应。结果CR3例（9.7%）,PR12例（38.7%）,SD8例（25.8%）,PD8例（25.8%）,有效率48.4%。主要不良反应为骨髓抑制、外周神经毒性、脱发。无治疗相关性死亡。结论多西他赛联合mFOLFOX方案治疗进展期胃癌近期疗效较好,药物毒副作用可耐受。

The combination of docetaxel and mFOLFOX in the treatment of advanced gastric cancer

Objective To elavulate the efficacy and toxicity of the combination of docetaxel and mFOLFOX in the treatment of advanced gastric cancer. Methods From June 2005 to March 2007,31 pa- tients with advanced gastric cancer were treated with docetaxel and mFOLFOX chemotherapy. The chemotherapy regimen consisted of docetaxel 60 mg/m2 （ day 1 ）, oxaliplatin 130 mg/m2 （ day 2 ） plus fluorouracil 2. 8 g/m2 continuous iv 46 h （day2）, leucovorin 300 mg （day 2 ） before use of fluorouracil, 3 weeks constituted one cycle, every patient was treated with more than 2 cycles. The response of the tumor and chemotherapy toxicity were observed for each patient. Results The overall response rate was 48.4% （9. 7% CR, 38. 7% PR）, SD was 25.8% and PD was 25.8%. The most common toxic reactions were bone marrow suppression, peripheral neurotoxicity and alopecia,but there was no chemotherapy-related death. Conclusion The combination of docetaxel plus mFOLFOX is a very effective and well tolerated regimen in the treatment of advanced gastric cancer.